Business
Research collaboration
Research collaboration.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 8073H Evgen Pharma PLC 05 August 2019 \n\n \n\n\n\n\n \n\n\n \n\n\n\n\n5 August 2019\nEvgen Pharma plc \n (\"Evgen\" or \"the Company\")\n \nResearch collaboration with King's College London and British Heart Foundation\n \nEvgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces its support for a new research collaboration between King's College London (\"King's\") and the British Heart Foundation (''BHF'') investigating how Evgen's SFX-01 can provide neurovascular protection in ischaemic stroke through Nrf2-regulated redox signalling.\n \nThe collaboration is being funded principally by the BHF as a PhD studentship. Evgen will supply SFX-01 to the project and has the right to negotiate a licence over any resultant intellectual property, on fair and reasonable preferential terms. If successful, the research will provide further insight into how SFX-01 mediates upregulation of Nrf2 in the blood-brain barrier endothelium, thereby enhancing neurovascular protection. \n \nThis work will build on the existing collaboration between Evgen and King's which has demonstrated vascular protection in murine models of ischaemic stroke.\n \nProfessor Giovanni Mann, Professor of Vascular Physiology at King's College London and supervisor for the project, commented: \"We are delighted to be collaborating again with Evgen Pharma and believe this project will build on our existing collaboration which showed great promise for SFX-01 in both stroke and potentially wider neuropsychiatric complications.''\n \nSteve Franklin, CEO of Evgen Pharma, said: ''We welcome the opportunity to continue working with Professor Mann in developing the opportunities for SFX-01 in neurology. Meanwhile, we look forward to our Phase IIb clinical data from SFX-01 in subarachnoid stroke which we will announce later this year.\"\n \nEnquiries:\n \n\n\n\n\nEvgen Pharma plc www.evgen.com\n\n\nvia Walbrook\n\n\n\n\nDr Stephen Franklin, CEO\n\n\n \n\n\n\n\nRichard Moulson, CFO\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nfinnCap www.finncap.com\n\n\n+44 (0) 20 7220 0500 \n\n\n\n\nGeoff Nash / Teddy Whiley (Corporate Finance)\n\n\n \n\n\n\n\nAlice Lane, Manasa Patil (ECM)\n\n\n \n\n\...